Aurobindo Pharma

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Aurobindo Pharma Limited
Public
Industry Pharmaceuticals
Founded 1986
Headquarters Hyderabad, Telangana, India
Key people
P.V.Ramprasad Reddy, , Mr. K. Nityananda Reddy, Mr. Govind, Dr. A Rama Mohana Rao, Madhan Mohan Reddy
Products Formulation, Active Pharmaceutical Ingredient, Organic Intermediates
Revenue 121.20 billion (US$1.8 billion)[1] (2015)
Number of employees
11,500[2] (March 2015)
Website www.aurobindo.com

Aurobindo Pharma Limited is a pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s area of activity includes six major therapeutic/product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics.[citation needed] The company markets these products in over 125 countries.[citation needed] Its marketing partners include AstraZeneca[3] and Pfizer.[4]

Company[edit]

The company commenced operations in 1988-89 with a single unit manufacturing semi-synthetic penicillin (SSP) in Puducherry. Aurobindo Pharma became a public company in 1992 and listed its shares in the Indian stock exchanges in 1995. Aurobindo Pharma also has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and cephalosporins, among others.

Aurobindo Pharma features among the top 10 companies in India in terms of consolidated revenues.[citation needed] Aurobindo exports to over 125 countries across the globe with more than 70% of its revenues derived out of international operations.

In 2014, Aurobindo purchased the generic operations of Actavis in 7 Western European countries for $41 million.[5] [6]

Legal issues[edit]

In December 2016, the attorneys general of 20 states filed a civil complaint accusing Aurobindo Pharma of a coordinated scheme to artificially maintain high prices for a generic antibiotic and diabetes drug. The complaint alleged price collusion schemes between six pharmaceutical firms including informal gatherings, telephone calls, and text messages.[7]

See also[edit]

References[edit]

  1. ^ http://www.aurobindo.com/docs/financial-results/2014-2015/afr_2014-15.pdf
  2. ^ "Slowdown Signals: IT, pharma only silver lining in dark jobs cloud". The Indian Express. Retrieved 26 December 2015. 
  3. ^ "Aurobindo Pharma signs supply pact with AstraZeneca", Economic Times, September 6, 2010
  4. ^ "Pfizer, Astra deals to drive Aurobindo Pharma’s growth", Economic Times, November 5, 2010
  5. ^ "Aurobindo Buys Actavis' European Operations". News: Industry Watch. Gen. Eng. Biotechnol. News (paper). 34 (4). 15 February 2014. p. 10. 
  6. ^ "Aurobindo To Buyout Actavis' EU Ops". Bloomberg TV India. Retrieved 20 January 2014. 
  7. ^ Thomas, Katie (2016-12-15). "20 States Accuse Generic Drug Companies of Price Fixing". The New York Times. Retrieved 2016-12-16. 

External links[edit]